Edition:
United States

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

4.95USD
11:10am EST
Change (% chg)

$-0.10 (-1.98%)
Prev Close
$5.05
Open
$5.10
Day's High
$5.20
Day's Low
$4.93
Volume
20,825
Avg. Vol
66,650
52-wk High
$8.25
52-wk Low
$2.35

Select another date:

Thu, Nov 16 2017

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

BRIEF-Arbutus’LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency

* Arbutus’ LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency (EMA) Source text for Eikon: Further company coverage:

BRIEF-Arbutus Biopharma reports Q3 loss per share $0.21

* Arbutus Biopharma Corp announces corporate update and third quarter 2017 financial results

BRIEF-Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement

* Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement to develop novel RNA-based personalized neoantigen immunotherapies for cancer patients

BRIEF-Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences

* Signed share purchase agreement with Roivant Sciences for sale of convertible preferred shares for $116.4 million

BRIEF-Arbutus announces topline results for ARB-1467 phase II Cohort 4

* Arbutus Biopharma Corp announces topline results for ARB-1467 phase ii cohort 4

BRIEF-Arbutus Biopharma Q2 loss per share $0.33

* Arbutus announces corporate update and second quarter 2017 financial results

BRIEF-Arbutus expects to take two experimental hep B drugs into human studies by mid-2018 - CEO

* Arbutus Biopharma expects to take two of its preclinical hep B drugs-in-development into human studies by mid-2018 - ceo Further company coverage:

BRIEF-Arbutus announces conclusion of LNP license agreement with Alexion

* Arbutus announces conclusion of LNP license agreement with Alexion

Select another date: